An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Berry to Support Asia’s Growing Healthcare Market with New Facility, Center of Excellence in Bangalore, India
Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Very Positive)
Tags
Rhea-AI Summary
Berry Global Group (NYSE: BERY) is set to begin production at its new manufacturing facility and healthcare center of excellence in Bangalore, India, starting April 2023. This Greenfield expansion aims to enhance access to healthcare solutions globally and will create over 500 jobs over the next eight years. The new facility will cater to the inhalation, nasal, ophthalmic, dispensing, and self-injection industries while supporting innovation through the R&D center, which plans to launch up to seven new products in 2023. Sustainability will be a priority, with 90% of the site's electricity sourced from renewable energy.
Positive
New manufacturing facility in Bangalore expected to begin operations in April 2023.
Creation of over 500 jobs over the next eight years.
Support for Asia’s domestic healthcare market growth.
Launch of up to seven new products in 2023, including innovative healthcare solutions.
90% of energy sourced from solar and wind, achieving ISCC Plus certification.
Negative
None.
Greenfield expansion project will create local jobs and improve global access to health products
EVANSVILLE, Ind.--(BUSINESS WIRE)--
Berry Global Group, Inc. (NYSE: BERY), a leader in the design, development, and production of patient-centered healthcare solutions, will begin product production at its new manufacturing facility and healthcare center of excellence in Bangalore, India as early as April 2023. Leveraging the company’s innovative research and development (R&D) solutions, this new Greenfield expansion project will:
Improve regional and global access to advanced healthcare solutions
Provide customers with necessary volume to support the forecasted growth for Asia’s domestic healthcare market
Boost India’s domestic economy by employing more than 500 new team members over the next eight years in Bangalore, commonly referred to as India’s Silicon Valley
“Healthcare companies have limited access to regional expertise and global capabilities needed to provide patient populations in Asia with modern healthcare solutions at scale,” said Tom Salmon, Berry Global's Chairman and CEO. “Our new facility and global healthcare center of excellence in Bangalore will support Asia’s growing demand for healthcare products, create new jobs, and, most importantly, benefit the lives of patient populations who have historically gone untreated and underdiagnosed.”
The new Bangalore plant will improve global patient access to products for the Inhalation, Nasal, Ophthalmic, Dispensing, and Self-injection industries. And the new Berry Global Healthcare R&D Center of Excellence will support the development of innovative solutions for existing and new applications to improve medicine administration and functionality, while helping customers’ meet ambitious sustainability goals.
The R&D center will be launching up to seven new products and projects in 2023 ranging from DPI Inhalers to plastics caps and closures. Included among these products will be Berry’s Pneumohaler, a lightweight, breath-actuated, multidose inhaler dose counter for the control and treatment of Asthma and Chronic Obstructive Pulmonary Disease (COPD). Several new medical packaging products will be available for sampling with industrial prototypes in March 2023.
Located in close proximity to some of the largest, generic pharmaceutical companies, the Bangalore site's ability to cater pharmaceutical packaging to U.S. regulatory requirements will enable the local manufacture of healthcare products, at a global scale. The site will use ISO class clean rooms, as well as leverage Berry’s experience submitting Active Drug Master Files (DMFs) to regulatory agencies, and providing active DMF and filling for regulated markets.
“Improved drug affordability and greater access to modern healthcare solutions are more important than ever in India, one of the most populated countries in the world. Our new facility and R&D center will benefit the domestic economy by creating new jobs and the regional economy overall by improving healthcare access and providing locally manufactured products,” said Jean-Marc Galvez, President of Consumer Packaging International.
Berry’s new Bangalore site will source the equivalent of around 90% of the facility’s electricity from solar and wind power. The site has also achieved the International Sustainability and Carbon Certificate (ISCC) Plus designation. ISCC Plus certified facilities support customer demand for more sustainable packaging by ensuring materials meet the ISCC’s standards for recycled, renewable, and recycled-renewable materials. This provides traceability along the supply chain and verifies certified companies meet high environmental and social standards.
The new Bangalore site will follow the same relentless pursuit of safety as Berry’s initial Bangalore facility, which has operated with zero safety incidents for more than fourteen years. This commitment to maintaining high safety standards will contribute to achieving Berry's ultimate safety goal of zero incidents of any type across its 265+ global locations and nearly 46,000 employees.
Several products developed at the Bangalore site will be available for sampling at the 2023 Pharmapack Paris exhibition. These products will include Berry’s innovative, patient-centric packaging and dispensing solutions, as well drug delivery devices for medicines and pharmaceuticals that meet the growing demand for sustainability and digitalization. Among these products will be Berry’s Activated Rispharm (with a Risdrop nozzle), a recyclable, multidose antimicrobial dropper that helps prevent eye microbial infections and produces 16X less waste than a unidose dropper. Activated Rispharm has received a gold rating for functionality from CPHI China.
Please contact us at Healthcare@berryglobal.com to learn more about Berry’s new manufacturing facility and Global R&D Center of Excellence in Bangalore.
About Berry Global
At Berry Global Group, Inc. (NYSE: BERY), we create innovative packaging and engineered products that we believe make life better for people and the planet. We do this every day by leveraging our unmatched global capabilities, sustainability leadership, and deep innovation expertise to serve customers of all sizes around the world. Harnessing the strength in our diversity and industry-leading talent of 46,000 global employees across more than 265 locations, we partner with customers to develop, design, and manufacture innovative products with an eye toward the circular economy. The challenges we solve and the innovations we pioneer benefit our customers at every stage of their journey. For more information, visit our website, or connect with us on LinkedIn or Twitter. (BERY- E)
